

YOUR INVITATION TO ATTEND:

GeneSight® in Clinical Practice

A MYRIAD GENETICS SPEAKER PRESENTATION

A clinical and scientific discussion focusing on the basics of pharmacogenomics and review of the GeneSight® Psychotropic report and clinical data. Q&A to follow.



PRESENTER

Raymund Tan, MD

Raymund Tan, M.D., is a child and adolescent psychiatrist, working at The Arc of the Ozarks' Autism and Neurodevelopmental Disorders Center. He was previously employed as a staff child/adolescent psychiatrist at Mercy Springfield from 2012-2023. He served as a member of the precision medicine team specializing in Pharmacogenomics at Mercy's Center for Precision Medicine. He holds multiple professional pharmacogenomic certifications from ACCP, ASHP, AMP, APGxA and AMIA. He completed his psychiatry residency and child and adolescent fellowship at the University of South Dakota Sanford School of Medicine. He completed his medical degree at M.H. Aznar College of Medicine and his undergraduate degree at Kansas State University. He completed a visiting fellowship in transcranial magnetic stimulation at Duke Medical Center. He is an assistant professor of clinical psychiatry for third-year medical students at the University of Missouri School of Medicine

DATE & TIME

Thursday, October 15, 2026
6:00pm

LOCATION

36 Restaurant
36 Main St.
Cape Girardeau, MO 63701

QUESTIONS

Everett Holman
Sales Executive
everett.holman@myriad.com
(417) 529-6560

RSVP

Please RSVP by
October 13, 2026

TO REGISTER

Click [Here](#) or scan
the QR code below



This event is not open to the general public. If you were not the original recipient of this invitation, please contact a GeneSight representative with your request to attend.

The GeneSight® Psychotropic test is a genetics-based decision support tool that analyzes clinically important genetic variations that may affect your patient's outcomes with certain psychiatric medications. Use of the GeneSight Psychotropic test can help inform your medication selection. The results show which medications may require dose adjustments, may be less likely to work, or may have an increased risk of side effects based on your patient's genetic makeup. The clinical validity, clinical utility, and economic utility of the GeneSight Psychotropic test have been evaluated in seven published, peer-reviewed clinical trials. In the GUIDED study, patients in the GeneSight arm experienced an 11% relative improvement in symptoms, a 30% relative improvement in response rates, and a 50% relative improvement in remission rates compared to treatment as usual at week 8.



6960 Cintas Blvd
Mason, OH 45040
866.260.2394



www.genesight.com